



Available online at
ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com



International meeting of the French Society of Neurology 2021

Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment



suppl.
Informations

A. Ducros^a, S. de Gaalon^b, C. Roos^c, A. Donnet^d, P. Giraud^e,
 E. Guégan-Massardier^f, M. Lantéri-Minet^g, C. Lucas^h, J. Mawet^c,
 X. Moissetⁱ, D. Valade^j, G. Demarquay^{k,*}

^a Department of neurology, Gui-de-Chauliac hospital, CHU Montpellier, university of Montpellier, 34000 Montpellier, France

^b Department of neurology, Laënnec hospital, CHU de Nantes, Nantes, France

^c Emergency headache center (centre d'urgences céphalées), department of neurology, Lariboisière hospital, Assistance publique-Hôpitaux de Paris, Paris, France

^d Centre d'évaluation et de traitement de la douleur, FHU INOVRAIN, hôpital de La Timone, Marseille, France

^e Department of neurology, Annecy Genevois hospital, Annecy, France

^f Department of neurology, Rouen university hospital, Rouen, France

^g Pain department, FHU InovPain, CHU Nice Côte Azur université, Nice, France

^h Centre d'évaluation et de traitement de la douleur, service de neurochirurgie, hôpital Salengro, CHRU de Lille, Lille, France

ⁱ Neuro-Dol, université Clermont Auvergne, CHU de Clermont-Ferrand, INSERM, Clermont-Ferrand, France

^j Department of neurosurgery, hôpital Pitié-Sapêtrière, Paris, France

^k Neurological hospital, Lyon, neuroscience research center (CRNL), INSERM U1028, CNRS UMR5292, Lyon, France

INFO ARTICLE

Article history:

Received 8 July 2021

Accepted 9 July 2021

Available online 30 July 2021

Keywords:

Episodic migraine

Chronic migraine

Guidelines

Acute treatment

Prophylactic treatment

Medication overuse

ABSTRACT

The French Headache Society proposes updated French guidelines for the management of migraine. This article presents the second part of the guidelines, which is focused on the pharmacological treatment of migraine, including both the acute treatment of attacks and the prophylaxis of episodic migraine as well as chronic migraine with and without medication overuse. The specific situations that can be encountered in women with migraine are also discussed, including pregnancy, menstrual migraine, contraception and hormonal replacement therapy.

© 2021 Published by Elsevier Masson SAS.

* Corresponding author.

E-mail address: genevieve.demarquay@chu-lyon.fr (G. Demarquay).

<https://doi.org/10.1016/j.neurol.2021.07.006>

0035-3787/© 2021 Published by Elsevier Masson SAS.

1. Introduction

Migraine is the second most common neurological disease after tension-type headache but, many affected patients remain undiagnosed and undertreated. Despite the existence of highly efficient treatments to alleviate headache (acute treatments) and decrease the frequency of attacks (preventative treatments), most patients with migraine in France remain undertreated. The French Headache Society has prepared revised guidelines to provide healthcare professionals with practical and up-to-date recommendations to optimize diagnosis and treatment of migraine, with the aim of improving the quality of life of affected patients and their relatives.

The guidelines have been divided into three parts. The first part presents guidelines for the diagnosis and assessment of migraine [1]. The second part, presented herein, is focused on the pharmacological treatment of migraine, including both the acute treatment of attacks and the prophylactic treatment of episodic migraine as well as chronic migraine with and without medication overuse. The specific situations that can be encountered in women with migraine are also discussed, including pregnancy, menstrual migraine, contraception and hormonal replacement therapy. The third part presents guidelines for the non-pharmacological treatments of migraine [2].

2. Methods

Methods are described in the first part of the updated guidelines [1] (Appendix 1).

3. Acute migraine treatment

3.1. What are the goals of acute migraine treatment?

The goals of acute migraine treatment are to obtain freedom of pain two hours after medication intake (significant pain relief is also acceptable) with 24 hours sustained response and without (or with minimal) adverse events. The relief of associated symptoms (photophobia, phonophobia, nausea and vomiting) and the ability to resume activities must also be evaluated.

In attacks of migraine with aura, the goals of acute treatment are the same as in attacks of migraine without aura for patients with headache. In addition, the acute treatment should ideally involve reduction of aura duration, but there is currently no such effective pharmacological treatment (Box 1).

3.2. What are the acute migraine treatments with demonstrated efficacy?

3.2.1. Analgesics (Table 1)

Evidence shows that paracetamol (acetaminophen) is effective in reducing migraine pain, but only in attacks of mild-to-moderate intensity with few bothersome symptoms [3,4].

Box 1. Management of migraine with aura.

1. Treatment of migraine attack

Instruct the patient to take a nonsteroidal anti-inflammatory drug (NSAID) at the beginning of the aura and a triptan at the onset of headache, even though the aura symptoms are still present. Triptans are probably not effective when given during the aura and before the onset of headache. No pharmacological treatment has proved efficacy to stop aura.

2. Prophylactic treatment

Regarding the initiation of a prophylactic treatment, follow the general recommendations for migraine (Rt15 and Rt16), considering that auras may be debilitating even in the absence of bothersome headache. Prescribe prophylactic treatments recommended for migraine in general. In some patients with troublesome auras, lamotrigine can be used and can be prescribed by a neurologist (Table 2a).

3. Prevention of stroke

Migraine with aura is associated with an increased risk of ischemic stroke. Educate the patients to prevent cardiovascular outcomes by encouraging smoking cessation, prescribing progestin-only contraceptive or non-hormonal contraception (see chapter V), regularly assessing blood pressure, and promoting regular exercise.

Evidence shows that the combination of paracetamol and caffeine with or without aspirin [5,6], and the combination of paracetamol and metoclopramide [7] are as effective as sumatriptan 50 mg at relieving acute migraine headache (level of evidence high). Evidence shows that acetylsalicylic acid (ASA; aspirin) with or without metoclopramide, and most nonsteroidal anti-inflammatory drugs (NSAIDs) are effective acute migraine treatments [8–13]. Because of the potential risk of medication overuse headache, the use of paracetamol, aspirin and NSAIDs should not regularly exceed 14 days per month [14,15].

Combination medications including caffeine increase the risk of migraine chronicization and their use must not exceed eight days per month [16]. Opioids are not recommended to treat migraine attacks as they exacerbate nausea, increase the risk of medication overuse headache, and carry the risk of misuse and abuse (level of evidence high) [14,15].

3.2.2. Triptans

Triptans are agonists of 5-HT_{1B}/5-HT_{1D} receptors. Triptans inhibit the release of vasoactive and pro-inflammatory neuropeptides [including calcitonin-gene-related peptide (CGRP)] and are vasoconstrictors. Seven triptans are available in France with different formulations (Table 2). Evidence shows that triptans are highly effective at relieving acute migraine pain (level of evidence high), and are superior to ergots, and superior or equal to NSAIDs and paracetamol (level of evidence medium) [17–20]. There is little difference in efficacy between different types of oral triptans, but a study in 2013 found that eletriptan was the most effective triptan at relieving pain at two and 24 hours, rizatriptan was the second most effective triptan at two hours but did not have the same

Table 1 – Non-specific acute migraine treatments (MA: specific French Market Approval for the acute treatment of migraine headache).

Analgesics	Level of evidence for efficacy	Strength of recommendation by the French Headache Society	Dose, route	Main side effects	Main contraindications ^a
Acetylsalicylate acid, aspirin	High	Strong	1000 mg (tablet, powder, disintegrating tablet) Maximum 3000 mg/day	Acetylsalicylate: digestive disorder, hemorrhage, allergy, Reye syndrome	Acetylsalicylate: active gastroduodenal ulcer, hemorrhagic risk, pregnancy, asthma, severe hepatic, cardiac or renal insufficiency, hypersensitivity, pregnancy
Acetylsalicylate + metoclopramide (MA)	High	Strong	900 mg + 10 mg (powder) Maximum 3/day	Metoclopramide: dyskinetic syndrome, restlessness psychiatric disorder, endocrine disorder	Metoclopramide: gastrointestinal hemorrhage, digestive perforation, history of dyskinesia, extrapyramidal syndrome, children
Paracetamol	High (in mild-to-moderate attacks)	High in mild attacks, moderate in moderate attacks, not recommended in severe attacks	500, 1000 mg (tablet) Maximum 4 g/day	Paracetamol: hepatic and hematologic toxicity	Severe hepatic insufficiency
Paracetamol + caffeine	High	Low	500 mg + 50 mg (tablet) Maximum 6 tablets/day	Caffeine: palpitation, insomnia	
NSAIDs	Level of evidence	Strength of recommendation	Dose, route	Main side effects	Main contraindications ^a
Diclofenac	High	Strong	25, 50, 100 mg (tablet) Maximum 150 mg/day	Hemorrhagic syndrome	Active gastroduodenal ulcer
Flurbiprofen	High	Strong	8.75 mg (tablet) Maximum 5 tablets/day	Digestive disorder, dyspepsia, nausea, diarrhea, constipation	Hypersensitivity to NSAIDs
Ibuprofen (MA)	High	Strong	200, 400 mg (tablet) Maximum 1200 mg/day	Dizziness, asthenia	Hemorrhagic risk (cerebral, digestive other), severe hepatic or renal insufficiency, pregnancy (after the 5th month)
Indomethacin	Medium	Moderate	25, 75 mg (tablet) 100 mg (suppository) Maximum 300 mg/day		
Ketoprofen (MA)	High	Strong	100, 150 mg (tablet) 100 mg (suppository) Maximum 200 mg/day		
Naproxen	High	Strong	550, 1000 mg (tablet) Maximum 1100 mg/day		

NSAIDs: nonsteroidal anti-inflammatory drugs.
^a Contraindications and side effects are not exhaustive, but listed according to frequency occurrence. Interactions are not given. Refer to Vidal.

Table 2 – Specific acute migraine treatments (MA: specific French Market Approval for the acute treatment of migraine headache).

Triptans	Level of evidence for efficacy	Strength of recommendation by the French Headache Society	Dose (route)	Main side effects	Main contraindications ^a
Almotriptan (MA)	High	Strong	12.5 mg (tablet) Maximum 25 mg/day	Paresthesia of extremities, nausea, feeling of cold, dizziness, asthenia, “chest syndrome” (feeling of constriction in the chest and neck), flushing, somnolence Rare cases of coronary spasms, severe hypertension, serotonin syndrome	Coronary heart disease Wolff Parkinson White syndrome Myocardial infarction Peripheral arterial disease Raynaud TIA and stroke Uncontrolled hypertension Serious hepatic or renal insufficiency Concurrent treatment with a MAO inhibitor Cross allergy with sulfonamides (except for rizatriptan and zolmitriptan)
Eletriptan (MA)	High	Strong	20 or 40 mg (tablet) Maximum 80 mg/day		
Frovatriptan (MA)	High	Strong	2.5 mg (tablet) Maximum 5 mg/day		
Naratriptan (MA)	High	Strong	2.5 mg (tablet) Maximum 5 mg/day		
Rizatriptan (MA)	High	Strong	5, 10 mg (tablets), 10 mg (disintegrating tablet) Maximum 20 mg/day		
Sumatriptan (MA)	High	Strong	50 mg (tablets) Maximum 300 mg/day 10/20 mg (nasal spray) Maximum 40 mg/day 6 mg (subcutaneous injection)		
Zolmitriptan (MA)	High	Strong	Maximum 12 mg/day 2.5 mg (tablet/disintegrating tablet) Maximum 10 mg/day Nasal spray 5 mg (not available in France)		
Gepants	Level of evidence	Strength of recommendation	Dose, route	Main side effects	Main contraindications ^a
Rimegepant (not available in France in 2021)	High	Strong	75 mg (tablet) Maximum 75 mg/day	Nausea Rare severe allergic reaction	History of hypersensitivity reaction to rimegepant
Ubrogepant (not available in France in 2021)	High	Strong	50 mg, 100 mg (tablets) Maximum 200 mg/day	Nausea, drowsiness Rare severe allergic reaction	History of hypersensitivity reaction to ubrogepant
Ditans	Level of evidence	Strength of recommendation	Dose, route	Main side effects	Main contraindications ^a
Lasmiditan (not available in France in 2021)	High	Moderate	50 mg, 100 mg (tablets) Maximum 200 mg/day No more than one dose should be taken in 24 hours (FDA)	Common (> 2%): dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, muscle weakness Significant driving impairment Central nervous system depression (dizziness, sedation) Rare (1%): hallucinations, euphoria Risk of misuse or abuse Rare cases of serotonin syndrome	Should be used with caution if used in combination with alcohol, cannabis or other CNS depressants No driving within the first 8 hours after intake (FDA)

NSAIDs: nonsteroidal anti-inflammatory drugs; FDA: Food and Drug Administration.

^a Contraindications and side effects are not exhaustive, but listed according to frequency occurrence. Interactions are not given. Refer to Vidal.

efficacy at 24 hours, and oral sumatriptan 100 mg was the third most effective treatment at two hours and maintained efficacy at 24 hours [18]. A systematic review of the effectiveness of the various routes and doses of sumatriptan concluded that subcutaneous sumatriptan 6 mg shows the greatest efficacy in terms of complete pain relief at two hours, provides more rapid pain relief than the other routes but has higher levels of adverse events (level of evidence high) [21]. Because of pharmacokinetic and genetic factors, a patient unresponsive to one triptan may respond to others, and a patient not tolerating one triptan may tolerate others [22].

Triptans are contraindicated in patients with increased cardiovascular risk. Evidence from post-marketing studies and real-life practice shows that triptans are safe and do not induce cardiovascular adverse events when contraindications are respected.

In patients with long migraine attacks, headache and other symptoms may return within 48 hours after initial successful treatment with a triptan. These relapses may be treated by repeating the triptan, but there is a risk of further relapses with this solution. In patients with troublesome relapses, simultaneous treatment at the beginning of the attacks with a combination of a triptan and an NSAID has proven efficacy [23]. Because of the potential risk of medication overuse headache, the use of triptan should not regularly exceed eight days per month [14,15].

Approximately 30–40% of persons with migraine experience insufficient efficacy and/or tolerability to triptans for acute treatment [24–26]. A recent systematic review suggested that a proportion of patients with insufficient efficacy and/or tolerability to one triptan may benefit from switching to a higher dose of the same triptan (sumatriptan 50 mg to 100 mg, eletriptan 40 mg to 80 mg), switching to a different formulation (nasal spray, subcutaneous, oral disintegrating tablet), switching to a different triptan, taking the triptan earlier in the attack, and/or combining a triptan with an NSAID (level of evidence fair) [22]. There are currently no available data about the proportion of patients who may benefit from a third triptan after failure to respond to an initial two triptans [22]. Women treated with triptans have a higher risk for headache recurrence and adverse events than men, despite similar rates of efficacy [27]. Other factors increasing risk of insufficient efficacy and/or tolerability to triptans include attacks with aura [28], severe baseline headache severity, photophobia, phonophobia, nausea, and comorbid depression [22].

3.2.3. Ergots

Ergotamine (combined with caffeine) is an older acute migraine treatment that is still occasionally used. Ergots are associated with an increased risk of serious adverse effects

(level of evidence high) [29] and are contraindicated in patients with increased cardiovascular risk. Dihydroergotamine (DHE) is the best tolerated of this class, but still has more adverse effects than NSAIDs and triptans.

3.2.4. Anti-emetics

Evidence shows that oral and intravenous metoclopramide, and oral domperidone are effective in the treatment of nausea associated with migraine attacks, and may improve the absorption of other oral acute migraine treatments (level of evidence high) [7,13,30,31].

3.2.5. Gepants

Gepants are small antagonists of the calcitonin gene-related peptide (CGRP) receptor. Evidence shows that oral ubrogepant and rimegepant are effective at relieving pain associated with acute migraine [32–34]. There is a lack of evidence regarding the efficacy of gepants relative to other antimigraine treatments and in patients having insufficient efficacy and/or tolerability to triptans [35]. Gepants seem to cause less side effects than triptans, but could potentially carry a cardiovascular risk, although evidence to support or refute this concern is not available at the moment [36]. Since some oral gepants are currently investigated in the prophylactic treatment of migraine, gepants could potentially be associated with a reduced risk of medication overuse headache as compared to the other acute migraine drugs, although currently available evidence is insufficient to support or refute this hypothesis. By June 2021, gepants have no market approval in France.

3.2.6. Ditans

Lasmiditan is a highly selective 5-HT_{1F} receptor agonist without vasoconstrictive properties. Evidence shows that lasmiditan is effective at relieving migraine pain [37–39]. There is a lack of evidence regarding the efficacy of lasmiditan relative to other antimigraine treatments and in patients having insufficient efficacy and/or tolerability to triptans. Lasmiditan does not constrict the coronary arteries either in vitro or in vivo, and does not appear to carry the same cardiovascular risk as triptans [36]. Adverse effects of lasmiditan include central nervous system depression and marked sleepiness. Therefore, the United States Food and Drug Administration (FDA) issued a warning that driving should be proscribed during eight hours after lasmiditan intake. Therapeutic doses of lasmiditan were associated with a significant increased risk of drug-liking effects as compared to placebo, suggesting there is a potential risk of lasmiditan misuse or abuse (level of evidence medium) [40]. Effects of lasmiditan in relation to medication overuse headache are unknown. As of June 2021, lasmiditan has no market approval in France.

3.3. Recommendations on acute migraine treatment

The recommendations are summarized in the [Table 3](#).

Table 3 – Recommendations on acute migraine treatment.		
Concerning education and initial strategy of acute treatment, we recommend to		Strength of the recommendation
Rt1	Explain the goals of acute treatment, namely complete relief of headache two hours after medication intake with 24 hours sustained response and without adverse events	Strong
Rt2	Explain to patients with migraine with aura that there is currently no pharmacological treatment proved effective in stopping aura	Strong
Rt3	Explain that acute treatments must be taken early (within one hour of headache onset), with an adequate dosage and a route adapted to the severity of digestive symptoms	Strong
Rt4	Explain that the use of acute treatments should be limited to a maximum of eight days per month, because overusing medication carries the risk of medication overuse headache	Strong
Rt5	Encourage patients to use a headache calendar (headache frequency, intensity and acute medication), which will be reviewed at each visit	Strong
Rt6	Prescribe an acute treatment with an NSAID and a triptan, both chosen according to previous treatments and patient's preference	Strong
Rt7	Provide an education about the strategy for acute migraine treatment: a. When headache is mild, the patient should take an NSAID, and add a triptan in case of insufficient response after one hour b. When headache is moderate or severe, the patient should take a triptan, and add an NSAID in case of insufficient response after one hour c. In migraine with aura, the patient should take an NSAID at the beginning of the aura and a triptan at the onset of headache	Strong
Rt8	Avoid prescribing opiates to treat migraine due to the risks of misuse, abuse, and of medication overuse headache	Strong
Rt9	Prescribe a combination of paracetamol and metoclopramide in patients with contraindications or intolerance to NSAIDs, aspirin and triptans	Moderate
Rt10	Prescribe oral or parenteral metoclopramide (suppository or intravenous) to treat attacks with severe nausea or vomiting	Strong
Rt11	Explain that the efficacy and tolerability of the acute treatment is evaluated after three attacks, and plan a follow-up visit	Strong
Concerning the evaluation and optimization of acute treatment, we recommend to		Strength of the recommendation
Rt12	Use the Migraine Treatment Optimization Questionnaire (M-TOQ) at each visit and optimize the acute treatment in any patient responding "No" to one or more items	Strong
Rt13	Choose one or several strategies to optimize efficacy and/or tolerability of acute treatment and educate the patient a. To treat as early as possible into the headache phase b. To increase the dose of NSAID and/or triptan when applicable c. To combine a triptan and an NSAID simultaneously when attacks are resistant to a triptan alone and/or when relapses are troublesome d. To switch to a non-oral formulation (NSAID suppository; sumatriptan nasal spray or subcutaneous) and/or add metoclopramide in case of bothersome digestive symptoms e. To switch the NSAID to another NSAID f. To combine a triptan	Strong
Rt14	Diagnose resistance to a. NSAIDs only after complete inefficacy of at least two NSAIDs, used with adequate dose and route, each tested on at least three distinct attacks b. Triptans only after complete inefficacy of at least two triptans, used with adequate dose and route, each tested on at least three distinct attacks	Strong
NSAIDs: nonsteroidal anti-inflammatory drugs.		

4. Prophylactic treatment

4.1. What are the goals of prophylactic treatment of migraine?

The preventative treatment aims at reducing monthly migraine days by at least 50% in episodic migraine and by

at least 30% in chronic migraine. Prophylaxis also aims at reducing consumption of acute treatments, intensity and duration of attacks, and improving quality of life. Most patients under prophylaxis will still have attacks, and must be instructed how to treat them (see above).

In migraine with aura, the aims are also to reduce the frequency, duration and severity of auras, but there is a lack of high-quality studies investigating the effectiveness of drugs

Table 4 – Oral prophylactic treatments: dosage, side effects and contraindications.

Treatment (French Market Approval, yes or no)	Level of evidence for efficacy	Strength of recommendation by the French Headache Society	Daily dosage Minimum– Maximum (mean daily dosage)	Main side effects	Main contraindications
Amitriptyline (yes)	High in EM Fair in CM	Strong in EM Moderate in CM	10–100 mg (25 mg) Once at dinner time	Dry mouth, somnolence, weight gain	Absolute: glaucoma, prostatic adenoma Relative: obesity
Beta-blocker Propranolol (yes)	High in EM Fair in CM	Strong in EM Weak in CM	20–240 mg (80 mg) BID or once in the morning (extended release)	Common: asthenia, poor tolerance to effort Rare: depression	Absolute: asthma, heart failure, atrio-ventricular block, bradycardia Relative: depression
Metoprolol (yes)	High in EM Unknown in CM	Strong in EM Not recommended in CM	50–200 mg (100 mg) Once in the morning (extended release)		
Nebivolol (no)	Medium in EM Unknown in CM	Moderate in EM Not recommended in CM	5–10 mg (10 mg) Once in the morning		
Atenolol (no)	High in EM Fair in CM	Moderate in EM Weak in CM	50–200 mg (100 mg) Once in the morning		
Timolol (no)	High in EM Unknown in CM	Moderate in EM Not recommended in CM	10–60 mg (20 mg) BID		
Candesartan (no)	Medium in EM Fair in CM	Strong in EM Weak in CM	8–32 mg (16 mg) BID or once a day	Hypotension	Absolute: heart failure, renal artery stenosis, renal impairment, pregnancy Relative: hypotension
Flunarizine (yes)	High in EM Fair in CM	Moderate in EM Weak in CM	5–10 mg (5 mg) Once in the evening Stop after 6 months	Common: somnolence, weight gain, depression Rare: parkinsonism	Depression, obesity, Parkinson disease, parkinsonism, pregnancy
Lisinopril (no)	Fair in EM Unknown in CM	Moderate in EM Not recommended in CM	5–40 mg (20 mg) Once a day	Hypotension, dry cough, exanthema, impaired renal function	Angio-edema, renal artery stenosis, renal impairment, hyperkalemia, pregnancy
Lamotrigine (no)	Fair in migraine with aura	Weak in migraine with aura Not recommended in migraine without aura	25–300 mg (100 mg) Once or twice a day	Common: dizziness, insomnia Rare: serious hypersensitivity reactions, depression, suicidal ideation	Absolute: hypersensitivity to lamotrigine, breastfeeding Relative: previous allergy to another antiepileptic
Levetiracetam (no)	Medium in EM Fair in CM	Weak in EM Weak in CM	500–3000 mg Twice a day	Irritability, depression	Relative: renal impairment
Oxetorone (yes)	Fair in EM Unknown in CM	Moderate in EM Not recommended in CM	60–180 mg (120 mg) Once in the evening	Common: somnolence Rare: diarrhea, parkinsonism	Parkinson disease, parkinsonism, pregnancy
Pizotifene (yes)	Medium in EM Unknown in CM	Moderate in EM Not recommended in CM	50–300 mg (150 mg) BID	Common: sedation, weight gain	Obesity, glaucoma, prostatic adenoma, pregnancy
Topiramate (yes)	High in EM High in CM	Strong in EM Strong in CM	50–200 mg (100 mg) Once or twice a day	Common: paresthesia, weight loss, cognitive effects (word-finding difficulties), depression Rare: renal calculi, acute myopia with secondary angle closure glaucoma	Absolute: hypersensitivity to topiramate, pregnancy, glaucoma, severe pulmonary disease, metformin use, hepatic disease, nephrolithiasis, renal failure Relative: depression, suicidal ideation
Valproate (no)	High in EM Medium in CM	Strong in EM Moderate in CM Do never use in women of childbearing potential	250–2000 mg (750 mg) Once in the evening or twice a day	Common: nausea, weight gain, somnolence, tremor, alopecia, ASAT, ALAT increase, hepatitis	Absolute: liver disease, pregnancy, mitochondrial disease Relative: obesity Do never use in women of childbearing potential
Venlafaxine (no)	Fair in EM Unknown in CM	Weak in EM Not recommended in CM	37.5–300 mg (75–150 mg) Once a day	Common: nausea, dry mouth, hyperhidrosis	Hypersensitivity to venlafaxine

specifically for such purposes. Since prophylactic drugs have been investigated in populations mixing migraine patients with and without aura, migraine with aura is mostly treated with the same preventatives as migraine without aura (Box 1).

4.2. What treatments are effective for migraine prophylaxis?

Oral medications with a demonstrated efficacy in the prophylaxis of migraine are listed in Table 4. A large meta-analysis showed efficacy in the prevention of episodic migraine in at least three randomized controlled trials (RCTs) against placebo for amitriptyline, flunarizine, metoprolol, pizotifen, propranolol, topiramate and valproate [41]. Effective drugs in episodic migraine with less than three RCTs against placebo showing efficacy, and available in France, include several beta-blockers (atenolol, bisoprolol, timolol) and two other antihypertensives (lisinopril, candesartan), one anti-epileptic (levetiracetam), one antidepressant (venlafaxine) and one antihistaminic (oxetorone). In addition, fair-quality evidence supports the use of lamotrigine in the prophylaxis of migraine with aura. A once-daily dosage might improve adherence to the oral migraine prophylactic drugs [29].

Evidence shows efficacy of anti-CGRP and anti-CGRP-receptor monoclonal antibodies (CGRP-MABs) in both episodic and chronic migraine. Evidence shows that onabotulinum toxin A is an effective prophylactic treatment of chronic migraine but not episodic migraine.

4.2.1. Antihypertensives

High-quality evidence shows that propranolol, the most well studied beta-blocker, is effective in episodic migraine [42]. A recent meta-analysis of four non-placebo-controlled studies suggests that propranolol may also have a benefit in chronic migraine, with an efficacy comparable to that of valproic acid and flunarizine [42]. Evidence shows that metoprolol reduces headache frequency in episodic migraine, while atenolol, bisoprolol and timolol have lower efficacy and have been less studied [42].

Two placebo-controlled trials showed that candesartan 16 mg is superior to placebo and non-inferior to propranolol in episodic migraine [43,44]. Candesartan was shown to be effective in chronic migraine in a single RCT [43]. Evidence from a single trial for each drug shows that telmisartan [45] and lisinopril [46] are effective in episodic migraine.

4.2.2. Flunarizine

Evidence from two meta-analyses shows that flunarizine, a calcium-channel blocker without blood pressure influence, is effective in the prophylaxis of episodic migraine [41,47]. Flunarizine also showed efficacy in chronic migraine in a single non-placebo-controlled randomized trial [48]. Flunarizine can induce parkinsonism, the risk of which increases with older age, presence of comorbidities, exposure to high doses and longer duration of exposure [49]. In France, prescription of flunarizine is limited to six months.

4.2.3. Antiepileptics

Topiramate and valproic acid are the most commonly studied antiepileptics used in migraine prophylaxis and evidence

shows they are both effective in episodic migraine [41]. Topiramate 100 mg/day has clearly demonstrated efficacy in the prevention of chronic migraine, both with and without medication overuse [50,51]. Sodium valproate may have some efficacy in chronic migraine [52,53].

Two meta-analyses showed that levetiracetam was effective in episodic migraine [41,54]. Levetiracetam also showed efficacy in chronic migraine in one study, but was inferior to valproic acid [53]. Currently, levetiracetam is not widely used in migraine prophylaxis in France.

Evidence from small-sized trials and a meta-analysis suggest that lamotrigine is effective in the prevention of migraine with aura, achieving a reduction in the frequency of attacks and the duration of aura (Box 1) [41,55]. There is not any proof of efficacy of lamotrigine in migraine without aura. Lamotrigine must not be used in the prophylaxis of migraine without aura.

4.2.4. Antidepressants

Evidence from old studies [56–58] and two meta-analyses shows that amitriptyline is superior to placebo to reduce headache by 50% in episodic migraine [41,59]. Data show that amitriptyline has an efficacy in episodic migraine comparable to that of propranolol [60] and topiramate [61]. Amitriptyline may have some efficacy in chronic migraine [62]. Some older studies have suggested that fluoxetine [63–66] and venlafaxine at a dosage of 150 mg [67,68] might reduce the frequency of migraine attacks. A 2015 Cochrane review concluded that the use of selective serotonin reuptake inhibitors (SSRIs) for migraine prophylaxis was not supported by evidence [69]. A 2020 systematic review and meta-analysis concluded that serotonin-norepinephrine reuptake inhibitors (SNRIs) were superior to placebo in the prophylaxis of migraine, and most of the analyzed trials included venlafaxine [70].

4.2.5. Pizotifen

Pizotifen was shown to be more effective than placebo in nine RCTs [41].

4.2.6. Oxetorone

There is very limited evidence that oxetorone is superior to placebo in the prophylaxis of episodic migraine [20]. Oxetorone has market approval in France and is widely used in primary and secondary care for migraine prophylaxis [71].

4.2.7. OnabotulinumtoxinA

OnabotulinumtoxinA has established efficacy in the prevention of chronic migraine with or without medication overuse, but is not superior to placebo for the treatment of episodic migraine (level of evidence high) [72]. OnabotulinumtoxinA proved superiority to placebo when administered according to the PREPPT RCT protocol with 155–195 units injected at 31–39 sites in seven muscles all over the face, skull and neck, repeated every three months [73,74]. At least six months of treatment (two cycles of injections) seem necessary to observe maximal efficacy [73,74]. Since the pivotal trials published in 2010, evidence showing efficacy, tolerance and safety of onabotulinumtoxinA in chronic migraine at long-term (108 weeks) have been published [75,76]. Side effects are minimal. OnabotulinumtoxinA should be administered

according to the PREEMPT injection protocol, i.e. injecting 155 U-195 U to 31–39 sites every 12-weeks.

4.2.8. Monoclonal anti-CGRP and anti-CGRP-receptor antibodies

Calcitonin-gene related peptide (CGRP) is the main neuropeptide released by the trigeminal nerve and responsible for migraine headache. Monoclonal antibodies targeting the CGRP pathway (CGRP-MABs) belong to a new specific therapeutic class, including erenumab, eptinezumab, fremanezumab and galcanezumab, the first blocking the CGRP-receptor and the other three blocking CGRP itself (Table 5). CGRP-MABs have demonstrated efficacy in the prevention of both episodic migraine and chronic migraine without and with medication overuse, including in patients refractory to two to four previous oral preventive treatments (level of evidence high) [77,78]. RCTs have demonstrated excellent safety and tolerability of the four CGRP-MABs in the short-term (at 3 months). During RCTs, the rate of discontinuation for adverse events was remarkably low. The overall incidence of adverse events was similar in active and placebo treatment groups, except for injection-site reactions (pain, erythema), which were more common with CGRP-MABs but were transient and mostly mild-to-moderate (level of evidence high). Post-hoc analyzes have shown the superiority of CGRP-MABs over placebo in the speed of onset of efficacy, the achievement of a super-response with 75% or even 100% reduction in the monthly number of migraine days, the rate of efficacy in the most severely affected patients (previous failure of prophylaxis and/or medication overuse), the reduction of migraine-related functional impact and the improvement of productivity and quality of life (level of evidence medium) [79].

No direct comparison has been made between the CGRP-MABs, but a recent meta-analysis showed no difference between them in terms of efficacy and safety (level of evidence high) [80]. There is currently no available data about the proportion of patients who may respond to a second CGRP-MAB after failure to respond to an initial one, and about the proportion of patients who may respond to the MAB targeting the CGRP-receptor after

failure to respond to one of the MABs targeting CGRP and vice-versa. A recent RCT compared erenumab to topiramate, but the results are not available [81]. The LIBERTY [82], FOCUS [83] and CONQUER [84] RCTs showed superiority of erenumab, fremanezumab and galcanezumab respectively over placebo in patients with a documented history of failure of two to four classical oral migraine preventative medications, because of inefficacy or intolerance (level of evidence high). The trial with eptinezumab is still ongoing. Based on these studies, the French Transparency Commission decided that erenumab, fremanezumab and galcanezumab was indicated in patients having at least eight monthly migraine days and a history of failure to at least two oral prophylactic medications. Only neurologists can prescribe CGRP-MABs in France.

There is currently no evidence about the long-term safety of CGRP-MABs. Given the vasodilation role of CGRP, a prolonged blockade of CGRP pathways might increase the consequences of a potential cardiac or cerebral ischemic event. There are currently not any warning signs from RCTs [77–84] and from extension phases of RCTs, including for erenumab with a follow-up of five years [85,86], but patients with a history of cardiovascular disorder were not included in the RCTs. There is a need for long-term pharmacovigilance surveys [87]. There are currently very limited data about CGRP-MABs and pregnancy. In a recent survey of the safety profile of erenumab, galcanezumab and fremanezumab in pregnancy, no specific maternal toxicities, patterns of major birth defects, or increased reporting of spontaneous abortion were found [88]. Finally, there are currently no data on the incidence and consequences of neutralizing antibodies during long-term treatment with CGRP-MABs. Given the cost of CGRP-MABs, there is an important need for large cost-efficacy studies [79].

4.3. What is the evidence for prophylactic treatment of medication overuse headache?

There has been a long debate about the practical strategy in patients with chronic migraine with medication overuse

Table 5 – Injectable prophylactic treatments: dosage, side effects and contraindications.

Active component (French Market Approval, yes or no)	Level of evidence for efficacy	Strength of recommendation by the French Headache Society	Daily dosage Minimum–Maximum (mean daily dosage)	Side effects	Contraindications
OnabotulinumtoxinA (yes)	High in CM Not efficient in EM	Strong in CM Not recommended in EM	31–39 injections of 155–195 UI (195 UI) in 7 muscular groups, quarterly	Injection site pain	Absolute: myasthenia gravis, amyotrophic lateral sclerosis
Anti-CGRP or CGRP-receptor antibodies					
Erenumab (yes)	High in EM	Strong in EM	70–140 mg SC monthly	Injection site pain or redness,	Myocardial infarction, stroke, TIA, uncontrolled vascular risk factor
Eptinezumab (no)	High in CM	Strong in CM	100–300 mg IV quarterly	constipation, allergy	Pregnancy
Fremanezumab (yes)	High in EM	Strong in EM	225 mg SC monthly		
Galcanezumab (yes)	High in CM	Strong in CM	675 mg SC quarterly		
	High in EM	Strong in EM	240 mg SC the first month, then 120 mg SC monthly		

headache (MOH). Some authors recommended a two months abrupt and complete withdrawal before considering the introduction of prophylaxis [89]. Nevertheless, when patients with MOH are treated solely by withdrawal without any other preventive treatment, about one-third cannot tolerate or will not complete the process, one-third withdraws and improves, and one-third withdraws but does not improve [89,90]. Furthermore, evidence shows that the frequency of headache is significantly reduced in patients with chronic migraine receiving prophylaxis with topiramate, onabotulinumtoxinA or CGRP-MABs, whether or not they overuse acute medication at inclusion (level of evidence high) [91]. Of note, patients overusing opioids were not included in CGRP-MABs trials. In

MOH, recent evidence suggests that the best therapeutic strategy is withdrawal combined with preventive treatment from the start (level of evidence medium) [92]. Evidence also suggests that educating patients about the risks of migraine chronicization induced by medication overuse can improve global outcomes (level of evidence fair) [93].

4.4. Recommendations for pharmacological prophylaxis of migraine

The recommendations are summarized in the Table 6. These recommendations will be updated after marketing approval of eptinezumab and oral gepants.

Table 6 – Recommendations for pharmacological prophylaxis of migraine.

Regarding the initiation of prophylactic treatment, we recommend to		Strength of the recommendation
Rt15	Determine individual patient's eligibility to prophylaxis based on the patient's preference, headache diary or calendar, criteria for severe migraine and chronic migraine, HIT-6 and HAD scales	Strong
Rt16	Initiate a prophylactic treatment in any patient <ol style="list-style-type: none"> Using acute medications eight days or more per month since at least three months With severe migraine according to French criteria With chronic migraine according to ICHD-3 criteria With a HIT-6 scale of 60 or more With debilitating migraine attacks despite optimization of acute treatment 	Strong
Regarding patient education and optimal follow-up plan, we recommend to		
Rt17	Explain the goals of prophylactic migraine treatment <ol style="list-style-type: none"> The objective is to reduce monthly migraine days by 50% in episodic migraine and by 30% in chronic migraine Efficacy will be judged during the third month of treatment (weeks 8–12) Prophylaxis also aims at reducing consumption of acute treatments, intensity and duration of attacks, and improving quality of life Failure can be due to insufficient efficacy and/or tolerability 	Strong
Rt18	Start an oral prophylaxis as monotherapy and at a low-dose, and increase progressively to achieve optimal daily dose, taking into account possible side effects	Strong
Rt19	Explain that adherence to the prophylaxis is mandatory. When appropriate, prescribe once-daily dosage to improve compliance	Strong
As first-line prophylaxis for episodic migraine, our recommendations are		Strength of the recommendation
Rt20	Prescribe propranolol or metoprolol as first-line medication in any suitable patient with episodic migraine, because of the high level of evidence of efficacy	Strong
Rt21	Prescribe amitriptyline, candesartan or topiramate as first-line medication in patients with episodic migraine not suitable to beta-blockers, depending on the patient's preferences and comorbidities	Strong
As first-line prophylaxis for chronic migraine, our recommendations are		Strength of the recommendation
Rt22	Prescribe topiramate as first-line medication in any suitable patient with chronic migraine, because of the high level of evidence of efficacy	Strong
Rt23	Prescribe another recommended prophylaxis in patients with chronic migraine not suitable to topiramate, depending on the patient's preferences and comorbidities	Strong
Rt24	In patients with chronic migraine and medication overuse headache, prescribe a first-line prophylactic medication and advise an ambulatory withdrawal of the overused acute medication	Strong
To evaluate and adapt the prophylactic treatment, our recommendations are		Strength of the recommendation
Rt25	Assess efficacy, tolerability, compliance, and burden of migraine by interview, review of the calendar, and systematic use of HIT-6 and HAD scales at each visit. The efficacy of the prophylaxis should be evaluated after the third month of treatment except for onabotulinumtoxinA whose efficacy should be evaluated after six months	Strong
Rt26	In case of efficacy and good tolerability, continue the prophylaxis for 6–12 months, then decrease slowly before considering cessation. Restart the same treatment if the frequency of attacks increases again during decrease or after cessation	Strong

Table 6 (Continued)

To evaluate and adapt the prophylactic treatment, our recommendations are		Strength of the recommendation
Rt27	In case of insufficient efficacy and/or tolerability, choose one or several strategies to optimize the prophylaxis, and educate the patient a. Check for compliance b. Check for medication overuse, including analgesics for non-headache pain c. In case of insufficient efficacy and good tolerability, increase daily doses to the maximal recommended dose with an acceptable tolerance d. Switch to another prophylaxis	Strong
Regarding switching prophylaxis in episodic migraine, our recommendations are		Strength of the recommendation
Rt28	After failure of the first prophylaxis in episodic migraine, select a second recommended medication, depending on the patient's preferences and comorbidities	Strong
Rt29	After failure of two prophylactic medications in patients with less than eight migraine days per month, select another recommended medication depending on the patient's preferences and comorbidities	Strong
Rt30	After failure of at least two prophylactic treatments in patients with at least eight monthly migraine days, prescribe a CGRP-MAB selected among erenumab, fremanezumab and galcanezumab, based on the patient's preferences	Strong
Regarding switching prophylaxis in chronic migraine, our recommendations are		Strength of the recommendation
Rt31	After failure of the first oral prophylaxis in chronic migraine, select a second recommended oral medication, based on the patient profile, comorbidities, and the patient's preferences	Strong
Rt32	After failure of at least two oral treatments including topiramate in chronic migraine, prescribe a treatment with onabotulinimtoxin A or a CGRP-MAB selected among erenumab, fremanezumab and galcanezumab, based on the patient's preferences	Strong
For prophylaxis of resistant or refractory migraine, our recommendations are		Strength of the recommendation
Rt33	After failure of a CGRP-MAB in a patient with refractory episodic migraine, consider switching to another CGRP-MAB, with or without combination with an oral prophylactic medication	Moderate
Rt34	After failure of a CGRP-MAB in a patient with refractory chronic migraine, consider switching to another CGRP-MAB, or to treatment with onabotulinimtoxin A, both with or without combination with an oral treatment	Moderate
CGRP-MABs: calcitonin-gene-related peptide-receptor monoclonal antibodies.		

5. Specific situations in women with migraine

5.1. Migraine and pregnancy

5.1.1. What is the impact of pregnancy on migraine?

Migraine without aura usually improves or even ceases during pregnancy, especially after the first trimester (level of evidence high) [94,95]. However, 20% of women with migraine will have at least one migraine attack during pregnancy [96]. Unlike migraine without aura, migraine with aura can persist, worsen or even start during pregnancy [94,95].

5.1.2. Which medications can be used for acute migraine treatment during pregnancy?

Evidence shows that paracetamol (acetaminophen) [97,98] and triptans have a good safety profile (level of evidence high) [99–104]. The French reference center for teratogenic agents (CRAT) recommends to favor sumatriptan after failure of paracetamol, and zolmitriptan or rizatriptan after failure of sumatriptan [105]. NSAIDs are contraindicated after 24 weeks of pregnancy due to the risk of premature closure of the ductus arteriosus [97]. NSAIDs exposure close to the conception may increase the risk of miscarriage (level of evidence fair) [106]. Some studies suggested to avoid NSAIDs during the first

trimester [97], but a recent large database study found that the risks of spontaneous abortion and major birth defects did not differ between women exposed and non-exposed to ibuprofen (level of evidence medium) [107].

5.1.3. Which medications can be used for migraine prophylaxis during pregnancy?

Beta-blockers are not associated with an increased risk of malformations (level of evidence high) [108–110]. Amitriptyline may be used [97,98,105] and studies [85,104] suggesting an increased risk of fetal/child adverse events are scarce (level of evidence fair). The French CRAT states that published data about the use of amitriptyline during pregnancy are numerous and reassuring [105]. Neonatal symptoms may rarely appear in the first days of life of newborns when the mother took high doses of amitriptyline until delivery. Symptoms are usually transient and mild (respiratory distress, hyperexcitability, tone disturbances, slowed transit, sedation). A neonatal withdrawal syndrome may also occur and seems to be favored by an abrupt cessation of amitriptyline before childbirth [105].

According to the French CRAT, venlafaxine may be used during pregnancy in women with depression requiring a pharmacological treatment, and may thus be used in women with depression and associated migraine during pregnancy.

5.1.4. Which migraine medications are contraindicated during pregnancy?

Valproic acid is contraindicated because of a significant increased risk of severe fetal malformations as well as of cognitive deficits, mental retardation and autism in children exposed in utero. Topiramate is contraindicated in pregnant women and in those who wish to become pregnant because of an increased risk of severe malformations in fetuses exposed in utero. Candesartan and lisinopril are contraindicated because of fetal renal toxicity [97,105]. All the ergots are contraindicated [105]. Because of the absence of data, CGRP-MABs should not be used during pregnancy.

5.1.5. Impact of migraine on pregnancy

A recent meta-analysis showed that migraine is associated with an increased risk of preeclampsia and low birth weight (level of evidence high) [86].

5.1.6. Recommendations for management of migraine before and during pregnancy

The recommendations are summarized in the Table 7.

5.2. Menstrual migraine

5.2.1. How to diagnose menstrual migraine?

ICHD-3 recognizes two types of attacks in relation with menstruation, which is defined as the endometrial bleeding resulting either from the normal menstrual cycle or from the withdrawal of exogenous estrogens [111]. *Pure menstrual migraine* is diagnosed when attacks are occurring exclusively on day 1 ± 2 (i.e., days -2 to $+3$, there is no day 0) of menstruation in at least two out of three menstrual cycles, and at no other times of the cycle. *Menstrually-related migraine* is diagnosed when attacks are occurring on day 1 ± 2 of menstruation in at least two out of three cycles, and additionally at other times of the cycle.

Many women over-report an exclusive association between migraine attacks and menstruation, and only 8% have pure menstrual migraine [112]. Compared to other migraine attacks, menstrual attacks are mostly without aura (level of evidence medium) [113,114], and are longer, more disabling, more often associated with nausea and less responsive to acute treatment (level of evidence fair) [112].

Table 7 – Recommendations for management of migraine in women desiring pregnancy and during pregnancy.

Recommendations for management of migraine in women desiring pregnancy		Strength of recommendation
Rw1	Explain that migraine can be treated during pregnancy and in case of breastfeeding but self-medication should be formally avoided	Strong
Rw2	Explain that migraine usually improves during pregnancy, notably after the first trimester and in migraine without aura	Strong
Rw3	Explain that migraine does not modify the overall outcome of pregnancy, but is associated with an increased risk of gravid hypertension and preeclampsia	Strong
Rw4	For acute migraine treatment in women desiring pregnancy a. Prescribe paracetamol for mild attacks b. Prescribe triptans for moderate or severe attacks c. Avoid NSAIDs and aspirin (> 500 mg/day) because of the potential risk of early miscarriage	Strong
Rw5	For the prophylaxis of migraine in women desiring a pregnancy a. Stop current prophylactic medication whenever possible b. Contraindicate sodium valproate, topiramate, candesartan, lisinopril, and CGRP-MABs c. When prophylaxis is necessary, propose a non-pharmacological approach (lifestyle changes, exercise, neuromodulation, acupuncture) and/or prescribe amitriptyline, propranolol or metoprolol	Strong
Recommendations for management of migraine during pregnancy		Strength of recommendation
Rw6	Plan regular follow-up visits during pregnancy when remission of bothersome attacks was not achieved during the first trimester	Strong
Rw7	For acute treatment of migraine during pregnancy a. Prescribe paracetamol for mild attacks b. Prescribe a triptan for moderate or severe attacks, and after failure of paracetamol. Favor sumatriptan and use rizatriptan or zolmitriptan after failure of sumatriptan c. Contraindicate NSAIDs and aspirin (> 500 mg/day) after 24 weeks of pregnancy, and limit their use before 24 weeks	Strong
Rw8	Regarding migraine prophylaxis during pregnancy a. Encourage lifestyle changes and adapted exercise to each woman b. Propose neuromodulation and acupuncture to women asking for a non-pharmacological approach c. When pharmacological prophylaxis is necessary, prescribe propranolol, metoprolol or amitriptyline (propranolol and amitriptyline can be used during breastfeeding)	Strong
Rw9	In case of bothersome migraine during pregnancy, the patient should be managed both by a neurologist and a gynecologist	Strong

NSAIDs: nonsteroidal anti-inflammatory drugs; CGRP-MABs: calcitonin-gene-related peptide-receptor monoclonal antibodies.

5.2.2. What are the effective treatments for menstrual migraine?

Triptans, NSAIDs, paracetamol, and the combination of aspirin with caffeine are effective acute treatments for menstrual migraine (level of evidence high) [112,114]. Women with frequent migraine including menstrual attacks are eligible for standard prophylactic medications. In women with a regular hormonal cycle, some studies have shown that menstrual attacks may be prevented by short-term perimenstrual (sequential) prophylaxis. Naproxen is effective (level of evidence fair) [115] and its use may be relevant in case of associated dysmenorrhea [116]. Three triptans were shown to be effective (frovatriptan and naratriptan 2.5 mg twice daily, zolmitriptan 2.5 mg three times daily) (level of evidence high) [117], but they were used at high daily doses and this strategy should be balanced with the limit of eight monthly days of intake in order to prevent triptan overuse. Cutaneous estradiol (1.5 mg/day for 7 days) is effective (level of evidence fair) [118], but its use may delay the attack some days later, following hormonal withdrawal (level of evidence fair) [116,118,119]. Overall, we do not recommend these short-term perimenstrual prophylactic strategies (strength of recommendation: strong against).

In eligible women, hormonal contraception can be used with the purpose of preventing menstrual migraine, either with an extended-cycle regimen and a shortened hormone-free interval, or with a continuous regimen (level of evidence fair) [118]. In patients with migraine with aura, combined hormonal contraception (CHC) is contraindicated because of the increased risk of stroke, and progesterone-only contraceptives can be used (see below).

5.2.3. Recommendations for management of menstrual migraine

The recommendations are summarized in the [Table 8](#).

5.3. Migraine, contraception and hormonal replacement therapy

5.3.1. Does contraception aggravate migraine?

There is no data on the risk of migraine for non-oral contraception and for oral combined hormonal contraception (CHC) containing estradiol. No study is available about the impact of the levonorgestrel intrauterine device on migraine.

5.3.2. Is there a vascular risk of contraception in migraine?

The risk of ischemic stroke is significantly increased in migraine with aura. CHC significantly increases the risk of

Box 2. Type of contraception recommended according to the arterial risk factors and type of migraine.

First step: check for arterial risk factors before prescriptions of hormonal contraception

- Age > 35
- Smoking, familial history of stroke or myocardial infarction
- Arterial hypertension
- Dyslipidemia
- Diabetes
- Obesity

Second step: choose contraception according to the arterial risk factors and type of migraine

- Migraine without aura
 - Absence of any arterial risk factor: every hormonal contraception can be used
 - ≥ 1 risk factor: oral combined contraception is contraindicated; progestin-only contraception is possible
- Migraine with aura
 - Oral combined contraception is contraindicated; progestin-only contraception is possible

stroke in woman with migraine with aura (level of evidence high) [120,121]. In addition, arterial risk factors (age > 35, smoking, familial history of stroke or myocardial infarction, arterial hypertension, dyslipidemia, diabetes, obesity) are synergic with migraine (level of evidence high) (Box 2). Progestative contraception is not associated with an increased risk of ischemic stroke (level of evidence medium) [119]. Levonorgestrel intrauterine device is not contraindicated in migraine with aura (level of evidence high).

5.3.3. What is the impact of menopause and hormonal replacement therapy (HRT) on migraine?

While menopause, especially natural menopause, is frequently associated with an improvement of migraine, perimenopause is often associated with more frequent migraine attacks [122]. The impact of hormone replacement therapy on migraine course is debated [116,119].

Table 8 – Recommendations for diagnosis and treatment of menstrual migraine.

Recommendations for diagnosis and treatment of menstrual migraine		Strength of the recommendation
Rw10	Diagnose menstrual migraine according to ICHD-3 criteria, with the use a prospective headache diary over three months	Strong
Rw11	Treat menstrual attacks following recommendations for any acute attack, i.e. with an NSAID and/or a triptan	Strong
Rw12	In women with bothersome menstrual migraine who are already under hormonal contraception, propose a continuous intake of the contraception or a shortened hormone-free interval	Strong
Rw13	Women with bothersome menstrual migraine, the treatment and especially hormonal interventions should be decided by the primary care physician and a gynecologist	Strong

5.3.4. Recommendations for contraception and hormonal replacement therapy in women with migraine

The recommendations are summarized in the [Table 9](#).

Table 9 – Recommendations for contraception and HRT prescription in women with migraine.		
Recommendations for contraception in women with migraine	Level of evidence	Strength of the recommendation
Rw14 Before prescribing any hormonal contraception, always screen for migraine, with and without aura, in addition to other arterial risk factors	High	Strong
Rw15 In women with migraine <i>without</i> aura a. CHC can be prescribed in the absence of any other arterial risk factor b. When any arterial risk factor is present, contraindicate CHC and propose progestin-only or non-hormonal contraception	High	Strong
Rw16 In women with migraine with aura, contraindicate CHC and propose progestin-only or non-hormonal contraception	High	Strong
Recommendations for HRT prescription in women with migraine	Level of evidence	Strength of the recommendation
Rw17 Before any HRT prescription, always screen for migraine with and without aura in addition to other arterial risk factors	High	Strong
Rw18 HRT is not contraindicated in migraine without other vascular risk factor	Medium	Strong

HRT: hormonal replacement therapy; CHC: combined hormonal contraception.

Disclosure of interest

ADU has received honoraria for consultancies or speaker panel from Abbvie, Amgen, Eli Lilly, Lundbeck, Novartis and TEVA. SdG received honoraria from Abbvie/Allergan, Boehringer, Lilly, Novartis, Teva. CR received consultant or speaker fees from Allergan/Abbvie, Homeperf, Lilly, Lundbeck, Novartis et Teva. ADO received honoraria from Allergan, Amgen, Lilly, Lundbeck, Novartis, TEVA. PG has received honoraria for consultancies or speaker panel from Abbvie, Lilly, Lundbeck, Novartis, TEVA, Allergan, Biogen Idec, Sanofi, Merck-Serono, Roche. EGM received honoraria Allergan, Bayer, BMS, Boehringer, Lilly, Lundbeck, Medtronic, Novartis, Pfizer TEVA. MLM has received financial support to the institution (département d'évaluation et traitement de la douleur du CHU de Nice and/or le FHU InovPain) and honoraria from Allergan, Amgen, Boston Scientific, Grunenthal, Lilly, Lundbeck, Medtronic, Novartis, Pfizer, ReckittBenckiser, Saint-Jude, Sanofi-Aventis, Teva, UPSA, Zambon. CL has received honoraria from Amgen, Grunenthal, Homeperf, Lilly, Lundbeck, Novartis, SOS oxygène, TEVA. JM has received consultant or speaker fees from Lilly, Teva and Novartis and financial support for congress from Amgen, Novartis, SOS Oxygène, Homperf and Elsevier. XM has received financial support from Allergan, Biogen, Bristol Myers Squibb, Grünenthal, Lilly, Teva, Merck-Serono, Novartis, Roche, and Sanofi-Genzyme and non-financial support from SOS Oxygène, not related to the submitted work. DV declare that he has no competing interest. GD has received honoraria for consultancies or speaker panel from Abbvie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis and TEVA.

Acknowledgements

The authors thank the following for their contributions to the writing group members: Colette Aguerre (psychologist), Isabelle Berger (neurologist), Virginie Corand (neurologist), Christelle Creac'h (neurologist), Denys Fontaine (neurosurgeon), Lou Grangeon (neurologist), Franck Henry (psychologist), Justine Hugon-Rondin (gynecologist), Guillaume Levavasseur (sport medicine, osteopathy), Lorraine Maitrot-Mantelet (gynecologist), Marc Martin (general practitioner, acupuncturist), Geneviève Plu-Bureau (gynecologist), Sylvain Redon (neurologist), Françoise Radat (psychiatrist), Jean Schoenen (neurologist).

The authors thank the following for their contributions to the reading group members: Haiel Alchaar (neurologist), Michèle Barege (neurologist), Blandine Bertin (pharmacist, pharmacovigilance), Pauline Boulan (neurologist), Alexandre Cauchie (general practitioner, pain physician), Judith Cottin (pharmacist, pharmacovigilance), Gwladys Fontaine (general practitioner pain physician), Johann Guillet (general practitioner, pain physician), Cédric Gollion (neurologist), Gérard Mick (neurologist, pain physician), Bénédicte Noelle (neurologist), Sabine Simonin (anesthesiologist, pain physician), Jacques Gaillard (pain physician), Johann Guillet (general practitioner, pain physician), Jean-Louis Lajoie (general practitioner, pain physician), Jerome Massardier (gynecologist), Mirela Muresan (neurologist), Mitra Najjar (neurologist), Anne Revol (neurologist), Roland Peyron (neurologist), Sophie Poupplin (pain physician, rheumatologist), Loic Rambaud (neurologist, pain physician), Vincent Soriot (pain physician), Valerie Wolff (neurologist).

The authors also thank Mr. Quentin Peccoux and Mrs. Sabine Debremaeker.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.neurol.2021.07.006>.

REFERENCES

- [1] Demarquay G, Moisset X, Lanteri-Minet M, de Gaalon S, Donnet A, Giraud P, et al. Revised guidelines of the French Headache Society for the diagnosis and management of migraine in adults. Part 1: diagnosis and assessment. *Rev Neurol* 2021 [in press].
- [2] Demarquay G, Mawet J, Guegan-Massardier E, de Gaalon S, Donnet A, Giraud P, et al. Revised guidelines of the French Headache Society for the diagnosis and management of migraine in adults. Part 3: non-pharmacological treatment. *Rev Neurol* 2021 [in press].
- [3] Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. *Arch Intern Med* 2000;160:3486–92. <http://dx.doi.org/10.1001/archinte.160.22.3486>.
- [4] Prior MJ, Codispoti JR, Fu M. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. *Headache* 2010;50:819–33. <http://dx.doi.org/10.1111/j.1526-4610.2010.01638.x>.
- [5] Pini LA, Guerzoni S, Cainazzo M, Ciccarese M, Prudenzano MP, Livrea P. Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, crossover study. *J Headache Pain* 2012;13:669–75. <http://dx.doi.org/10.1007/s10194-012-0484-z>.
- [6] Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. *Headache* 2005;45:973–82. <http://dx.doi.org/10.1111/j.1526-4610.2005.05177.x>.
- [7] Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev* 2013;CD008040. <http://dx.doi.org/10.1002/14651858.CD008040.pub3>.
- [8] Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG, et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. *Neurology* 2002;58:1660–5. <http://dx.doi.org/10.1212/wnl.58.11.1660>.
- [9] Suthisisang CC, Poolsup N, Suksomboon N, Lertpipometha V, Tepwitukgid B. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. *Headache* 2010;50:808–18. <http://dx.doi.org/10.1111/j.1526-4610.2010.01635.x>.
- [10] Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev* 2013;CD008783. <http://dx.doi.org/10.1002/14651858.CD008783.pub3>.
- [11] Suthisisang C, Poolsup N, Kittikuluth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. *Ann Pharmacother* 2007;41:1782–91. <http://dx.doi.org/10.1345/aph.1K121>.
- [12] Anthony M, Lance JW. Indomethacin in migraine. *Med J Aust* 1968;1:56–7.
- [13] Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev* 2013;CD008041. <http://dx.doi.org/10.1002/14651858.CD008041.pub3>.
- [14] Diener H-C, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, et al. Pathophysiology, prevention, and treatment of medication overuse headache. *Lancet Neurol* 2019;18:891–902. [http://dx.doi.org/10.1016/S1474-4422\(19\)30146-2](http://dx.doi.org/10.1016/S1474-4422(19)30146-2).
- [15] Krymchantowski AV, Jevoux CC, Krymchantowski AG, Vivas RS, Silva-Néto R. Medication overuse headache: an overview of clinical aspects, mechanisms, and treatments. *Expert Rev Neurother* 2020;20:591–600. <http://dx.doi.org/10.1080/14737175.2020.1770084>.
- [16] Nowaczewska M, Wiciński M, Kaźmierczak K. The ambiguous role of caffeine in migraine headache: from trigger to treatment. *Nutrients* 2020;12(8):2259. <http://dx.doi.org/10.3390/nu12082259>.
- [17] Cameron C, Kelly S, Hsieh S-C, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. *Headache* 2015;55(Suppl. 4):221–35. <http://dx.doi.org/10.1111/head.12601>.
- [18] Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. *Cephalalgia Int J Headache* 2014;34:258–67. <http://dx.doi.org/10.1177/0333102413508661>.
- [19] Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT_{1B/1D} agonists) in acute migraine treatment: a meta-analysis of 53 trials. *Lancet Lond Engl* 2001;358:1668–75. [http://dx.doi.org/10.1016/S0140-6736\(01\)06711-3](http://dx.doi.org/10.1016/S0140-6736(01)06711-3).
- [20] Lanteri-Minet M, Valade D, Géraud G, Lucas C, Donnet A, Société française d'étude des migraines et des céphalées. [Guidelines for the diagnosis and management of migraine in adults and children]. *Rev Neurol (Paris)* 2013;169:14–29. <http://dx.doi.org/10.1016/j.neurol.2012.07.022>.
- [21] Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults – overview of Cochrane reviews. *Cochrane Database Syst Rev* 2014;CD009108. <http://dx.doi.org/10.1002/14651858.CD009108.pub2>.
- [22] Leroux E, Buchanan A, Lombard L, Loo LS, Bridge D, Rousseau B, et al. Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. *Adv Ther* 2020;37:4765–96. <http://dx.doi.org/10.1007/s12325-020-01494-9>.
- [23] Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. *Cochrane Database Syst Rev* 2016;4:CD008541. <http://dx.doi.org/10.1002/14651858.CD008541.pub3>.
- [24] Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ. Triptan nonresponders: do they exist and who are they? *Cephalalgia Int J Headache* 2013;33:891–6. <http://dx.doi.org/10.1177/0333102413480756>.
- [25] Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT_{1B/1D} agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. *Cephalalgia Int J Headache* 2002;22:633–58. <http://dx.doi.org/10.1046/j.1468-2982.2002.00404.x>.

- [26] Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. *Headache* 2013;53:1300-11. <http://dx.doi.org/10.1111/head.12154>.
- [27] van Casteren DS, Kurth T, Danser AHJ, Terwindt GM, MaassenVanDenBrink A. Sex differences in response to triptans: a systematic review and meta-analysis. *Neurology* 2021;96:162-70. <http://dx.doi.org/10.1212/WNL.00000000000011216>.
- [28] Hansen JM, Charles A. Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs. *J Headache Pain* 2019;20:96. <http://dx.doi.org/10.1186/s10194-019-1046-4>.
- [29] Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. *J Headache Pain* 2019;20:57. <http://dx.doi.org/10.1186/s10194-018-0899-2>.
- [30] Eken C. Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis. *Am J Emerg Med* 2015;33:331-7. <http://dx.doi.org/10.1016/j.ajem.2014.11.013>.
- [31] Golikhatir I, Cheraghmakani H, Bozorgi F, Jahanian F, Sazgar M, Montazer SH. The efficacy and safety of prochlorperazine in patients with acute migraine: a systematic review and meta-analysis. *Headache* 2019;59:682-700. <http://dx.doi.org/10.1111/head.13527>.
- [32] Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. *Cephalalgia Int J Headache* 2016;36:887-98. <http://dx.doi.org/10.1177/0333102416653233>.
- [33] Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs. placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II Randomized Clinical Trial. *JAMA* 2019;322:1887-98. <http://dx.doi.org/10.1001/jama.2019.16711>.
- [34] Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet Lond Engl* 2019;394:737-45. [http://dx.doi.org/10.1016/S0140-6736\(19\)31606-X](http://dx.doi.org/10.1016/S0140-6736(19)31606-X).
- [35] Tfelt-Hansen P, Loder E. The emperor's new gepants: are the effects of the new oral CGRP antagonists clinically meaningful? *Headache* 2019;59:113-7. <http://dx.doi.org/10.1111/head.13444>.
- [36] van Hoogstraten WS, MaassenVanDenBrink A. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. *J Headache Pain* 2019;20:54. <http://dx.doi.org/10.1186/s10194-019-1007-y>.
- [37] Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. *Neurology* 2018;91:e2222-3. <http://dx.doi.org/10.1212/WNL.0000000000006641>.
- [38] Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. *Brain J Neurol* 2019;142:1894-904. <http://dx.doi.org/10.1093/brain/awz134>.
- [39] Kniewel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Krege JH, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. *Cephalalgia Int J Headache* 2020;40:19-27. <http://dx.doi.org/10.1177/0333102419889350>.
- [40] Willbraham D, Berg PH, Tsai M, Liffick E, Loo LS, Doty EG, et al. Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study. *J Clin Pharmacol* 2020;60:495-504. <http://dx.doi.org/10.1002/jcph.1543>.
- [41] Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. *PLoS One* 2015;10:e0130733. <http://dx.doi.org/10.1371/journal.pone.0130733>.
- [42] Jackson JL, Kuriyama A, Kuwatsuka Y, Nickoloff S, Storch D, Jackson W, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. *PLoS One* 2019;14:e0212785. <http://dx.doi.org/10.1371/journal.pone.0212785>.
- [43] Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double crossover study. *Cephalalgia Int J Headache* 2014;34:523-32. <http://dx.doi.org/10.1177/0333102413515348>.
- [44] Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. *JAMA* 2003;289:65-9. <http://dx.doi.org/10.1001/jama.289.1.65>.
- [45] Diener HC, Gendolla A, Feuersenger A, Evers S, Straube A, Schumacher H, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. *Cephalalgia Int J Headache* 2009;29:921-7. <http://dx.doi.org/10.1111/j.1468-2982.2008.01825.x>.
- [46] Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover study. *BMJ* 2001;322:19-22. <http://dx.doi.org/10.1136/bmj.322.7277.19>.
- [47] Stubberud A, Flaaen NM, McCrory DC, Pedersen SA, Linde M. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. *Pain* 2019;160:762-72. <http://dx.doi.org/10.1097/j.pain.0000000000001456>.
- [48] Lai K-L, Niddam DM, Fuh J-L, Chen S-P, Wang Y-F, Chen W-T, et al. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. *Acta Neurol Scand* 2017;135:476-83. <http://dx.doi.org/10.1111/ane.12626>.
- [49] Lin W, Lin C-L, Hsu CY, Wei C-Y. Flunarizine induced Parkinsonism in migraine group: a nationwide population-based study. *Front Pharmacol* 2019;10:1495. <http://dx.doi.org/10.3389/fphar.2019.01495>.
- [50] May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. *Nat Rev Neurol* 2016;12:455-64. <http://dx.doi.org/10.1038/nrneurol.2016.93>.
- [51] Lantéri-Minet M, Demarquay G, Alchaar H, Bonnin J, Cornet P, Douay X, et al. [Management of chronic daily headache in migraine patients: medication overuse headache and chronic migraine. French guidelines (French Headache Society, French Private Neurologists Association, French Pain Society)]. *Rev Neurol (Paris)* 2014;170:162-76. <http://dx.doi.org/10.1016/j.neurol.2013.09.006>.
- [52] Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. *J Headache Pain* 2008;9:37-41. <http://dx.doi.org/10.1007/s10194-008-0002-5>.
- [53] Kashipazha D, Ghadikolaie HS, Siavashi M. Levetiracetam in compare to sodium valproate for prophylaxis in chronic migraine headache: a randomized double-blind clinical

- trial. *Curr Clin Pharmacol* 2017;12:55–9. <http://dx.doi.org/10.2174/1574884712666170329094419>.
- [54] Yen P-H, Kuan Y-C, Tam K-W, Chung C-C, Hong C-T, Huang Y-H. Efficacy of levetiracetam for migraine prophylaxis: a systematic review and meta-analysis. *J Formos Med Assoc Taiwan Yi Zhi* 2020;120:755–64. <http://dx.doi.org/10.1016/j.jfma.2020.08.020>.
- [55] Buch D, Chabriat H. Lamotrigine in the prevention of migraine with aura: a narrative review. *Headache* 2019;59:1187–97. <http://dx.doi.org/10.1111/head.13615>.
- [56] Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. *J Neurol Neurosurg Psychiatry* 1973;36:684–90. <http://dx.doi.org/10.1136/jnnp.36.4.684>.
- [57] Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. *Neurology* 1976;26:121–7. <http://dx.doi.org/10.1212/wnl.26.2.121>.
- [58] Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. *Arch Neurol* 1979;36:695–9. <http://dx.doi.org/10.1001/archneur.1979.00500470065013>.
- [59] Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. *BMJ* 2010;341:c5222. <http://dx.doi.org/10.1136/bmj.c5222>.
- [60] Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. *Arch Neurol* 1987;44:486–9. <http://dx.doi.org/10.1001/archneur.1987.00520170016015>.
- [61] Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group non-inferiority trial in adult migraineurs. *Clin Ther* 2009;31:542–59. <http://dx.doi.org/10.1016/j.clinthera.2009.03.020>.
- [62] Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. *Clin Neurol Neurosurg* 2010;112:463–6. <http://dx.doi.org/10.1016/j.clineuro.2010.02.004>.
- [63] Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. *Headache* 1992;32:101–4. <http://dx.doi.org/10.1111/j.1526-4610.1992.hed3202101.x>.
- [64] d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. *Headache* 1999;39:716–9. <http://dx.doi.org/10.1046/j.1526-4610.1999.3910716.x>.
- [65] Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. *Headache* 1994;34:497–502. <http://dx.doi.org/10.1111/j.1526-4610.1994.hed3409497.x>.
- [66] Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. *Cephalalgia Int J Headache* 1998;18:283–6. <http://dx.doi.org/10.1046/j.1468-2982.1998.1805283.x>.
- [67] Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. *Headache* 2005;45:144–52. <http://dx.doi.org/10.1111/j.1526-4610.2005.05029.x>.
- [68] Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. *Clin Neurol Neurosurg* 2004;107:44–8. <http://dx.doi.org/10.1016/j.clineuro.2004.03.004>.
- [69] Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. *Cochrane Database Syst Rev* 2015;CD011681. <http://dx.doi.org/10.1002/14651858.CD011681>.
- [70] Wang F, Wang J, Cao Y, Xu Z. Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis. *Reg Anesth Pain Med* 2020;45:323–30. <http://dx.doi.org/10.1136/rapm-2019-101207>.
- [71] Lanteri-Minet M, Alchaar H, Besson G, Billé-Turc F, Bouillat J, Brudon F, et al. [Pharmaco-epidemiological study on the prophylactic treatment of migraine. National inquiry on attitude to prescription practices by primary care physicians and neurologists in France]. *Rev Neurol (Paris)* 2000;156:1106–12.
- [72] Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, et al. Botulinum toxins for the prevention of migraine in adults. *Cochrane Database Syst Rev* 2018;6:CD011616. <http://dx.doi.org/10.1002/14651858.CD011616.pub2>.
- [73] Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalalgia Int J Headache* 2010;30:793–803. <http://dx.doi.org/10.1177/0333102410364676>.
- [74] Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia Int J Headache* 2010;30:804–14. <http://dx.doi.org/10.1177/0333102410364677>.
- [75] Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. *J Headache Pain* 2018;19:13. <http://dx.doi.org/10.1186/s10194-018-0840-8>.
- [76] Winner PK, Blumenfeld AM, Eross EJ, Orejudos AC, Mirjah DL, Adams AM, et al. Long-term safety and tolerability of onabotulinumtoxinA treatment in patients with chronic migraine: results of the COMPEL Study. *Drug Saf* 2019;42:1013–24. <http://dx.doi.org/10.1007/s40264-019-00824-3>.
- [77] Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies – successful translation from bench to clinic. *Nat Rev Neurol* 2018;14:338–50. <http://dx.doi.org/10.1038/s41582-018-0003-1>.
- [78] Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. *Lancet Lond Engl* 2019;394:1765–74. [http://dx.doi.org/10.1016/S0140-6736\(19\)32504-8](http://dx.doi.org/10.1016/S0140-6736(19)32504-8).
- [79] Schoenen J, Manise M, Nonis R, Gérard P, Timmermans G. Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention. *Rev Neurol (Paris)* 2020;176(10):788–803. <http://dx.doi.org/10.1016/j.neurol.2020.04.027>.
- [80] Deng H, Li G-G, Nie H, Feng Y-Y, Guo G-Y, Guo W-L, et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis. *BMC Neurol* 2020;20:57. <http://dx.doi.org/10.1186/s12883-020-01633-3>.
- [81] Clinicaltrials.gov. Head-to-head study of erenumab against topiramate in patients with episodic and chronic migraine (HER-MES). NCT03828539 n.d.
- [82] Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. *Lancet Lond Engl*

- 2018;392:2280-7. [http://dx.doi.org/10.1016/S0140-6736\(18\)32534-0](http://dx.doi.org/10.1016/S0140-6736(18)32534-0).
- [83] Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet Lond Engl* 2019;394:1030-40. [http://dx.doi.org/10.1016/S0140-6736\(19\)31946-4](http://dx.doi.org/10.1016/S0140-6736(19)31946-4).
- [84] Mulleners WM, Kim B-K, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet Neurol* 2020;19:814-25. [http://dx.doi.org/10.1016/S1474-4422\(20\)30279-9](http://dx.doi.org/10.1016/S1474-4422(20)30279-9).
- [85] Bérard A, Zhao J-P, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. *BMJ Open* 2017;7:e013372. <http://dx.doi.org/10.1136/bmjopen-2016-013372>.
- [86] Aukes AM, Yurtsever FN, Boutin A, Visser MC, de Groot CJM. Associations between migraine and adverse pregnancy outcomes: systematic review and meta-analysis. *Obstet Gynecol Surv* 2019;74:738-48. <http://dx.doi.org/10.1097/OGX.0000000000000738>.
- [87] Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, de Boer I, et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? *J Headache Pain* 2019;20:27. <http://dx.doi.org/10.1186/s10194-019-0979-y>.
- [88] Nosedá R, Bedussi F, Gobbi C, Zecca C, Ceschi A. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. *Cephalalgia Int J Headache* 2021. <http://dx.doi.org/10.1177/0333102420983292> [333102420983292].
- [89] Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication overuse headache: a randomized controlled open-label trial. *Cephalalgia Int J Headache* 2018;38:225-36. <http://dx.doi.org/10.1177/0333102417737779>.
- [90] Scher AI, Rizzoli PB, Loder EW. Medication overuse headache: an entrenched idea in need of scrutiny. *Neurology* 2017;89:1296-304. <http://dx.doi.org/10.1212/WNL.0000000000004371>.
- [91] Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Láinez M, et al. European Academy of Neurology guideline on the management of medication overuse headache. *Eur J Neurol* 2020;27:1102-16. <http://dx.doi.org/10.1111/ene.14268>.
- [92] Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L, et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. *JAMA Neurol* 2020;77(9):1069-78. <http://dx.doi.org/10.1001/jama.2020.1179>.
- [93] Grande RB, Aaseth K, Benth JS, Lundqvist C, Russell MB. Reduction in medication overuse headache after short information. The Akershus study of chronic headache. *Eur J Neurol* 2011;18:129-37. <http://dx.doi.org/10.1111/j.1468-1331.2010.03094.x>.
- [94] Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, Polatti F, et al. Course of migraine during pregnancy and postpartum: a prospective study. *Cephalalgia Int J Headache* 2003;23:197-205. <http://dx.doi.org/10.1046/j.1468-2982.2003.00480.x>.
- [95] Kvisvik EV, Stovner LJ, Helde G, Bovim G, Linde M. Headache and migraine during pregnancy and puerperium: the MIGRA-study. *J Headache Pain* 2011;12:443-51. <http://dx.doi.org/10.1007/s10194-011-0329-1>.
- [96] Tanos V, Raad EA, Berry KE, Toney ZA. Review of migraine incidence and management in obstetrics and gynaecology. *Eur J Obstet Gynecol Reprod Biol* 2019;240:248-55. <http://dx.doi.org/10.1016/j.ejogrb.2019.07.021>.
- [97] de Gaalon S, Donnet A. Headaches during pregnancy. *Rev Neurol (Paris)* 2020;177(3):195-202. <http://dx.doi.org/10.1016/j.neurol.2020.05.012>.
- [98] Negro A, Delaruelle Z, Ivanova TA, Khan S, Ornello R, Raffaelli B, et al. Headache and pregnancy: a systematic review. *J Headache Pain* 2017;18:106. <http://dx.doi.org/10.1186/s10194-017-0816-0>.
- [99] Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. *Eur J Epidemiol* 2013;28:759-69. <http://dx.doi.org/10.1007/s10654-013-9831-x>.
- [100] Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. *Headache* 2014;54:1158-72. <http://dx.doi.org/10.1111/head.12375>.
- [101] Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. *Headache* 2015;55:490-501. <http://dx.doi.org/10.1111/head.12500>.
- [102] Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after antimigraine triptan use: a prospective observational cohort study. *Cephalalgia Int J Headache* 2018;38:1081-92. <http://dx.doi.org/10.1177/0333102417724152>.
- [103] Harris G-ME, Wood M, Ystrom E, Nordeng H. Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: follow-up from the Norwegian Mother and Child Cohort Study. *Paediatr Perinat Epidemiol* 2018;32:247-55. <http://dx.doi.org/10.1111/ppe.12461>.
- [104] Saldanha JJ, Cao W, Bhuma MR, Konnyu KJ, Adam GP, Mehta S, et al. Management of primary headaches during pregnancy, postpartum, and breastfeeding: a systematic review. *Headache* 2021;61:11-43. <http://dx.doi.org/10.1111/head.14041>.
- [105] Centre de référence des agents tératogènes; 2020. <https://www.lecrat.fr>. n.d.
- [106] Li D-K, Ferber JR, Odouli R, Quesenberry C. Use of nonsteroidal anti-inflammatory drugs during pregnancy and the risk of miscarriage. *Am J Obstet Gynecol* 2018;219. <http://dx.doi.org/10.1016/j.ajog.2018.06.002> [275.e1-275.e8].
- [107] Dathe K, Fietz A-K, Pritchard LW, Padberg S, Hultsch S, Meixner K, et al. No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester - Evaluation of the national Embryotox cohort. *Reprod Toxicol Elmsford N* 2018;79:32-8. <http://dx.doi.org/10.1016/j.reprotox.2018.05.003>.
- [108] Bergman JEH, Lutke LR, Gans ROB, Addor M-C, Barisic I, Cavero-Carbonell C, et al. Beta-blocker use in pregnancy and risk of specific congenital anomalies: a European case-malformed control study. *Drug Saf* 2018;41:415-27. <http://dx.doi.org/10.1007/s40264-017-0627-x>.
- [109] Bateman BT, Heide-Jørgensen U, Einarsdóttir K, Engeland A, Furu K, Gissler M, et al. β -blocker use in pregnancy and the risk for congenital malformations: an international cohort study. *Ann Intern Med* 2018;169:665-73. <http://dx.doi.org/10.7326/M18-0338>.

- [110] Wu Y, Yao J-W, Xu L-J, Chen M, Wan L. Risk of congenital malformations in offspring of women using β -blockers during early pregnancy: an updated meta-analysis of observational studies. *Br J Clin Pharmacol* 2021;87:806-15. <http://dx.doi.org/10.1111/bcp.14561>.
- [111] Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. *Cephalalgia Int J Headache* 2018;38:1-211. <http://dx.doi.org/10.1177/0333102417738202>.
- [112] Burch R. Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review. *Headache* 2020;60:200-16. <http://dx.doi.org/10.1111/head.13665>.
- [113] Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing greater recognition. *Lancet Neurol* 2021. [http://dx.doi.org/10.1016/S1474-4422\(20\)30482-8](http://dx.doi.org/10.1016/S1474-4422(20)30482-8).
- [114] Maasumi K, Tepper SJ, Kriegler JS. Menstrual migraine and treatment options: review. *Headache* 2017;57:194-208. <http://dx.doi.org/10.1111/head.12978>.
- [115] Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo-controlled study. *Headache* 1990;30:705-9. <http://dx.doi.org/10.1111/j.1526-4610.1990.hed3011705.x>.
- [116] MacGregor EA. Menstrual and perimenopausal migraine: a narrative review. *Maturitas* 2020;142:24-30. <http://dx.doi.org/10.1016/j.maturitas.2020.07.005>.
- [117] Hu Y, Guan X, Fan L, Jin L. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. *J Headache Pain* 2013;14:7. <http://dx.doi.org/10.1186/1129-2377-14-7>.
- [118] Sacco S, Merki-Feld GS, Aegidius KL, Bitzer J, Canonico M, Gantenbein AR, et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). *J Headache Pain* 2018;19:76. <http://dx.doi.org/10.1186/s10194-018-0896-5>.
- [119] Sacco S, Merki-Feld GS, Aegidius KL, Bitzer J, Canonico M, Kurth T, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). *J Headache Pain* 2017;18:108. <http://dx.doi.org/10.1186/s10194-017-0815-1>.
- [120] Tietjen GE, Maly EF. Migraine and ischemic stroke in women. A narrative review. *Headache* 2020;60:843-63. <http://dx.doi.org/10.1111/head.13796>.
- [121] Ornello R, Canonico M, Merki-Feld GS, Kurth T, Liddegaard Ø, MacGregor EA, et al. Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. *Expert Rev Neurother* 2020;20:313-7. <http://dx.doi.org/10.1080/14737175.2020.1730816>.
- [122] MacGregor EA. Migraine, menopause and hormone replacement therapy. *Post Reprod Health* 2018;24:11-8. <http://dx.doi.org/10.1177/2053369117731172>.